Increased production of interferon-γ by Leishmania homologue of the mammalian receptor for activated C kinase-reactive CD4+ T cells among human blood mononuclear cells: An early marker of exposure to Leishmania?

Scandinavian Journal of Immunology

Volumn 58, Issue 2, 2003, Pages 201-210

  Bourreau, E ^a   Pascalis, H ^a,b   Prevot G ^a,b   Kariminia, A ^a   Jolly, N ^c   Milon, G ^d   Buffet, P ^c   Michel, R ^e   Meynard, J B ^e   Boutin, J P ^e   Aschimoff, D ^e,f   Launois, P ^a  

^a INSTITUT PASTEUR DE LA GUYANE   (French Guiana)

^b UNIVERSITÉ DES ANTILLES ET DE LA GUYANE   (France)

^c Cent Nacional de la Recherche   (France)

^d INSTITUT PASTEUR   (France)

^e Institut de Medecine de la Reproduction   (France)

^f Serv Med 9ieme Regiment d'I   (French Guiana)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE; GAMMA INTERFERON; LEISHMANIA HOMOLOGUE OF THE MAMMALIAN RECEPTOR FOR ACTIVATED C KINASE; PARASITE ANTIGEN; PROTEIN KINASE; UNCLASSIFIED DRUG;

ARTICLE; CELLULAR IMMUNITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LEISHMANIA; LEISHMANIASIS; LYMPHOCYTE CULTURE; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIGENS, PROTOZOAN; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; HUMANS; IMMUNOMAGNETIC SEPARATION; INTERFERON TYPE II; LEISHMANIA GUYANENSIS; LEISHMANIASIS, MUCOCUTANEOUS; LEUKOCYTES, MONONUCLEAR; MALE; PROSPECTIVE STUDIES; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; TROPICAL CLIMATE;

EID: 0042848845     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2003.01280.x     Document Type: Article

References (27)

1. Armijos RX, Weigel MM, Aviles H, Maldonado R, Recines J. Field trials of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months follow-up. J Infect Dis 1998;177:1352-7.
2. Khalil EA, El Hassan AM, Zijlstraa EE et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-bind, BCG-controlled trial in Sudan. Lancet 2000;356:1565-9.
3. Momeni AZ, Jalayer T, Emamjomeh M et al. A randomised double-bind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 1999;17:466-72.
4. Sharifi I, FeKri AR, Aflatonian MR et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998;351:1540-3.
5. Mossman TR, Coffmann RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
6. Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol 1995;13:151-77.
7. + T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 2002;168:3992-4000.
8. Huber M, Timms E, Mak TW, Rollinghoff M, Lohoff M. Effective and long lasting immunity against the parasite Leishmania major. In: CD8-Deficient Mice. Infect. Immun 1998;66:3698-700.
9. + T cells. Int Immunol 1991;3:587-97.
10. Wang ZE, Reiner SL, Hatam F et al. Targeted activation of CD8 cells and infection of beta-microglobulin-deficient mice fails to confirm a primary protective role for CD8 cells in experimental leishmaniasis. J Immunol 1993;151:2077-86.
11. + T cells associated with cure of human cutaneous leishmaniasis. Infect Immun 1994;62:2614-8.
12. Da-Cruz AM, Bittar R, Mattos M et al. T-cell-mediated immune responses in patients with cutaneous or mucosal leishmaniasis: long term evaluation after therapy. Clin Diagn Lab Immunol 2002;9:251-6.
13. + antigen-specific T cells. Infect Immun 1999;67:5559-66.
14. Mendonca SC, De Luca PM, Mayrink W et al. Characterization of human T lymphocyte-mediated immune responses induced by a vaccine against American tegumentary leishmaniasis. Am J Trop Med Hyg 1995;53:195-201.
15. Mougneau E, Altare F, Wakil E et al. Expression cloning of a protective Leishmania antigen. Science 1995;286:563-6.
16. + T cells in BALB/c mice infected with Leishmania major instruct Th2 cell development and susceptibility to infection. Immunity 1997;6:541-9.
17. Gurunathan S, Sacks DL, Brown DR et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 1997;186:1137-47.
18. Pingel S, Launois P, Fowell DJ et al. Altered ligands reveal plasticity in the T-cell response to a pathogenic epitope. J Exp Med 1999;189:1111-20.
19. + T cells generated in response to LACK in naïve subjects never exposed to Leishmania. Eur J Immunol 2002;32:510-20.
20. Maasho K, Satti I, Nylèn S, Guzman G, Koning F, Akuffo H. A Leishmania homologue of receptors for activated C-kinase (LACK) induces both interferon-γ and interleukin-10 in natural killer cells of healthy blood donors. J Infect Dis 2000;182:570-8.
21. + T cells that induce gamma interferon production in patients with localized cutaneous leishmaniasis during an early stage of infection. Infect Immun 2002;70:3122-9.
22. Grimaldi P, Tesh RB, McMahon-Pratt D. A review of the geographic distribution and epidemiology of leishmaniasis in the New World. Am J Trop Med Hyg 1989;41:687-725.
23. Banzet B. Epidemies de leishmanioses cutanées chez les militaires en opération en Guyane Française. Medecine Tropicale 2000;60: 297-302.
24. Louis JA, Moedder E, Behin R, Hengers HD. Recognition of protozoan parasite antigen by murine T lymphocytes. Eur J Immunol 1979;9:2437-40.
25. Field J, Nikawa J, Broek D et al. Purification of a Ras-responsive adenylyl cyclase complex from Saccharomyces cerevisiae by use of an epitope addition method. Mol Cell Biol 1988;8:2159-65.
26. + T cells unresponsive to IL-12. J Infect Dis 2001;183:953-9.
27. Rocha PN, Almeida RP, Bacellar O et al. Down-regulation of Th1 type of response in early human American cutaneous leishmaniasis. J Infect Dis 1999;180:1731-4.